T-Cell Engager for Autoimmune Disease Summit on October 14-16, 2025 in Boston, United States

The T-Cell Engager for Autoimmune Disease Summit is the first and only industry-dedicated meeting designed to unlock the full potential of TCEs beyond oncology into autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis. As the field accelerates, following promising clinical signals and major biopharma partnerships, this summit unites leading immunologists, protein engineers, and translational experts to drive TCEs into and through clinical development in autoimmunity.

From overcoming cytokine release syndrome to exploring targets beyond B cell depletion, this is your one-stop shop for the latest science, clinical insights and strategic thinking on TCEs for inflammatory diseases.

URLs:

Tickets: https://go.evvnt.com/3153518-0?pid=10008

Brochure: https://go.evvnt.com/3153518-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Primary - Conference + Workshop Day: USD 4197.00,

Primary - Conference Only: USD 2999.00,

Academic - Conference + Workshop Day: USD 3597.00,

Academic - Conference Only: USD 2599.00,

Vendor - Conference + Workshop Day: USD 5097.00,

Vendor - Conference Only: USD 3699.00

Speakers: Antoine Sreih Vice President and Director - Medical and Clinical Development CULLINAN THERAPEUTICS, INC., Daniel Nunez Senior Director, Computational Biology Cabaletta Bio, Ivana Tosevski Head of Preclinical Safety and Pharmacology Leader CDR-Life Inc, Jay Mei Founder, Chairman, and Chief Executive Officer Antengene, John Desjarlais Chief Scientific Officer Xencor, Juha Punnonen CDO Hinge Bio, Inc., Kate Rochlin COO IN8Bio, Ken Song Chairman, President and CEO Candid Therapeutics, Mohosin Sarkar Vice President, Head of Research and Development TBD Pharmaceuticals, Neely Mozaffarian Chief Medical Officer and Head of Development Ouro Medicines, Nikhil Mutyal Head of Search and Evaluation- Respiratory and Immunology AstraZeneca, Patrick Alexander Baeuerle Chief Scientific Advisor and Chairman of Scientific Advisory Board CULLINAN THERAPEUTICS, INC., Ricardo Grieshaber-Bouyer Professor of Medicine, Head of the Clinical Trial Unit Friedrich-Alexander-Universität Erlangen-Nürnberg, Scott Plevy Chief Scientific Officer Oblenio Bio, Steven Quayle Senior Vice President and Head of Research and Translational Medicine Cue Biopharma, Tatiana Ort Head of Bioscience and Immunology AstraZeneca, Warren Li Senior Vice President , Head of Research and Program Management Overland Therapeutics, Zhinan Xia Founder,President and Chief Scientific Officer Abimmune